Traditional fibrosis scoring systems, such as NASH CRN and METAVIR, rely on semi-quantitative staging that categorizes disease into discrete levels. While clinically useful, these systems are limited by inter- and intra-observer variability, low sensitivity to subtle changes, and dependence on staining techniques. These factors can reduce reproducibility and make it difficult to detect incremental progression or regression of fibrosis, particularly in clinical trial settings.

AI-based fibrosis analysis improves reproducibility by applying standardized algorithms to every tissue sample, eliminating variability associated with human interpretation. This ensures that the same biopsy yields consistent results regardless of the pathologist, institution, or timepoint. Studies have shown that AI-assisted tools can significantly reduce discrepancies in fibrosis scoring and improve agreement across observers, making them particularly valuable in multi-center clinical trials.

Quantitative fibrosis assessment treats fibrosis as a continuous biological process rather than a categorical stage. AI-powered platforms measure collagen content, spatial distribution, and architectural features with high precision, enabling the detection of subtle changes that may not be visible through conventional histology. This increased sensitivity allows for more accurate monitoring of disease progression and treatment response.

FibroSIGHT™ Plus is a laboratory-developed test that introduces the key advancement of AI-based quantitative assessment of liver fibrosis. It provides clinicians with a sensitive and consistent tool with which to better characterize individual patients. FibroSIGHT™ Plus leverages HistoIndex’s stain-free Second Harmonic Generation (SHG) and Two-Photon Excitation Fluorescence (TPEF) imaging technology to capture detailed tissue structure and collagen fibers with high consistency – eliminating the variability associated with conventional tissue staining. The output is a value on a continuous scale, offering detailed and objective measurement of fibrosis severity across the wide spectrum of fibrosis in MASH.

MASH clinical trials often involve large, multi-center patient cohorts, requiring consistent and efficient analysis of liver biopsy samples. Traditional manual pathology workflows can create bottlenecks due to limited expert availability and time-intensive review processes. AI-based platforms enable high-throughput analysis, reduce turnaround times, and ensure standardized evaluation across sites, making them essential for scalable trial design.

AI is not designed to replace pathologists but to augment their expertise. AI-based tools function as decision-support systems, providing quantitative data that enhances diagnostic confidence and consistency. Pathologists remain critical for contextual interpretation, validation, and clinical decision-making, while AI improves efficiency and reduces variability.

AI-driven fibrosis analysis enhances drug development by improving endpoint sensitivity, reducing variability, and enabling the detection of subtle treatment effects. This allows clinical trials to better assess therapeutic efficacy, potentially reduce sample size requirements, and accelerate development timelines. Quantitative, reproducible data also supports stronger regulatory submissions.

Second harmonic generation (SHG) imaging is a stain-free technique that visualizes collagen structures based on their intrinsic optical properties. This approach eliminates variability associated with staining and enables high-resolution imaging of collagen architecture. When combined with AI analysis, SHG imaging provides highly reproducible and quantitative assessments of fibrosis.

AI integration streamlines clinical workflows by automating fibrosis quantification, standardizing reporting, and enabling faster data processing. Solutions like FibroSIGHT™ Plus allow clinicians and researchers to access quantitative insights without disrupting established processes. This improves efficiency while maintaining clinical oversight.

Yes, AI-based fibrosis analysis is increasingly applicable in both research and clinical practice. By providing standardized and quantitative outputs, these tools help bridge the gap between clinical trials and real-world diagnostics. This enables more consistent interpretation of biopsy results and supports the translation of research findings into patient care.